Chelsea Therapeutics, Inc. CEO to Review NORTHERA(TM) NDA and Provide an Update on Upcoming Advisory Committee Meeting During Presentation at Biotechnology Industry Organization (BIO) CEO

CHARLOTTE, N.C., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that during a presentation at the 14th Annual BIO CEO and Investor Conference president and CEO, Dr. Simon Pedder, plans to provide an update regarding the company’s New Drug Application (NDA) for NORTHERA™ (droxidopa), an overview of key issues identified in the FDA briefing document received by the company and anticipated discussion points for the upcoming Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting scheduled for February 23rd.

MORE ON THIS TOPIC